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SUMMARY
Proteomic approach has allowed large-scale studies of protein expression in different tis-
sues and body fluids in discrete conditions and/or time points. Recent advances of meth-
odologies in this field have opened new opportunities to obtain relevant information on 
normal and abnormal processes occurring in the human body. In the current report, the 
main proteomics techniques and their application to human disease study are reviewed.
Keywords: Proteomics; neoplasms; polyacrylamide gel electrophoresis; mass spectrom-
etry; diseases.
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Figure 1 – Different methodologies can be combined in 
proteomic studies. Methodologies more commonly used 
involve protein extraction from the sample, separation by 
one- (1-D) or two-dimensional (2-D) electrophoresis and/or 
liquid chromatography, ionization, fragmentation, peptide 
analysis and detection, and data analysis.
INTRODUCTION
In the search for molecular markers that could assist in the 
early diagnosis and treatment of several human diseases, 
including cancer, many studies have focused on changes in 
genes, their transcripts, and protein products involved in 
important cellular processes.
Recent methodological approaches allowing a wide 
gene expression analysis include cDNA1 microarray tech-
nique, serial analysis of gene expression (SAGE)2, and 
large-scale sequencing techniques using state-of-the-art 
equipment3. The study of gene expression by using these 
techniques gives a molecular profile and provides oppor-
tunities to identify important changes occurring at the 
RNA level. However, transcript analysis is impaired by a 
susceptibility to breakdown and a nonconformity between 
the transcript and the protein concentration4. Moreover, 
information on processes modulating protein function 
and activity, such as post-translational changes, protein-
protein interactions, transportation, and breakdown are 
lost in RNA analysis5. Thus, it is important that, in parallel 
to data derived from the genome and clinical data, infor-
mation on protein differences across normal and altered 
tissue and/or body fluids are also collected so that the 
mechanisms involved in human disease are understood, 
with consequent benefit for patients.
To identify and understand the differences, it is crucial 
to know the set of proteins encoded by the genome and de-
fined as the proteome6. Indeed, the proteome is not only 
the sum of products translated from genomic sequences, 
but it also includes proteins resulting from post-transcrip-
tional and post-translational processing, as well as com-
plexes formed by these biomolecules7. In addition to its 
great complexity, the proteome is dynamic and its profile 
changes according to physiological status and phases of cell 
differentiation. Some estimates suggest that over a million 
different types of proteins are present in cells, tissues, and 
body fluids in discrete conditions and/or time points8. The 
term proteomics regards the study of this set of molecules, 
that are directly or indirectly responsible for control-
ling all or nearly all biological processes. As well-defined 
by Valledor and Jorrin9, proteomics is the descriptive and 
quantitative study of proteins, from those in a subcellular 
organelle to those in an ecosystem, as well as their varia-
tions in the population, changes in response to the environ-
ment or resulting from normal or altered development, and 
modifications and interactions with other proteins.
METHODOLOGY IN PROTEOMICS
Many of the techniques employed in proteomics focus 
on the identification of biomarkers, but they are limited 
for direct medical applications. Other techniques have a 
potential for automation and use in clinical routine with 
diagnostic purpose, and allow the analysis of many kinds 
of samples and changes in the pattern of protein expres-
sion associated with a disease. Overall, methodologies 
employed in proteomics (Figure 1) may be classified into 
bottom-up and top-down types. The former, also termed 
shotgun7, includes liquid chromatographic separation of 
peptides derived from tryptic digestion of complex protein 
solutions, followed by mass spectrometry (MS) analysis. 
The top-down method, in contrast, is a process in which 
intact proteins (not peptides) undergo MS analysis. Bot-
tom-up approaches have many advantages, such as sen-
sitivity and reproducibility, even for complex proteomes, 
such as cell lysates and serum. However, the responses 
obtained are fragments of a whole, and although protein 
identification based on a few peptides is possible, post-
translational modifications are not recognized. In addi-
tion, a peptide may either be lost during chromatography, 
or appropriate mass spectra may not be generated. Thus, 
top-down proteomics has received a great deal of attention 
from the scientific community10.
Combining these approaches with other processes, 
such as subcellular fractionation or protein immunopre-
cipitation, can be quite effective to enrich a sample with 
low-abundance compounds or cell organelles of interest11. 
Fresh samples constitute the first choice in these studies, 
but as they are difficult to obtain, particularly in rare dis-
eases, some methods have been developed for paraffin em-
bedded specimens12.
PROTEIN SEPARATION BY ONE- AND TWO-DIMENSIONAL  
ELECTROPHORESIS
To separate proteins by one- (1-D) and two-dimensional 
(2-D) electrophoresis, the molecules must be initially iso-
lated from biological materials, such as tissues and body 
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fluids. Appropriate protein extraction is crucial to obtain 
good electrophoretic results. As a function of the various 
types and sources of biological samples, the extraction 
procedure needs individual optimization. In most cases, 
proteins need to be solubilized, disaggregated, denatured, 
and treated with disulfide bond reducing agents13.
In typical 2-D electrophoresis, proteins are separated 
in two consecutive steps. At the first step, termed iso-
electric focusing (IEF), molecules migrate in a polyacryl-
amide gel with an immobilized14 or amphoteric buffer-
generated15 pH gradient until they reach a point (pH) in 
which their charge equals zero (isoelectric point – IP). 
At the second step, proteins undergo an electropho-
resis whose direction is perpendicular to IEF in poly-
acrylamide gel containing sodium dodecyl sulfate 
(SDS-PAGE), being separated according to their mo-
lecular mass. This second step is similar to a 1-D elec-
trophoresis, in which molecules are directly applied to 
SDS-PAGE and separated according to their size.
In order to make protein bands or spots visible (1-D 
and 2-D, respectively), gels are stained by Coomassie 
blue, silver nitrate, or other commercially available dyes. 
In 2-D gels, 100 to 2,000 spots can be visualized, each 
one of them containing one to several proteins, and some 
post-translational changes are easily detected as vertical-
ly or horizontally aligned trains of spots. After gel image 
digitalization and use of computer tools, the background 
material is extracted, the spots are compared, and the 
data are normalized and statistically analyzed for protein 
volume or intensity quantification16. A simpler protocol is 
used for 1-D gels, whose bands of interest or full runs are 
sliced and analyzed17. Proteins found in these slices or in 
2-D gel spots are digested into peptides by trypsin, with 
cleavage being made after arginine or lysine residues.
Many modifications have already been made in 
the 2-D original protocol. One of the most recent and 
popular is based on labelling cyanine fluorescent dyes 
reacting with lysine or cysteine residues. This labeling 
gave rise to a technique, the Fluorescent 2-D Differential 
In-Gel Electrophoresis (2-D DIGE)18, allowing for the 
analysis of two protein samples marked with different 
fluorochromes in the same gel, thus reducing inter-gel 
variation and improving the efficiency and accuracy of 
the method.
Although 1-D and 2-D electrophoresis techniques can 
generate much information, they have limitations. One 
of the most important limitations is the presence of some 
proteins in elevated concentrations, especially in certain 
body fluids, which makes electrophoretic migration of 
less abundant proteins more difficult. Another limitation 
is that the extraction of intact proteins from the gel for 
top-down analysis is difficult, but some attempts to cir-
cumvent this problem have been made10.
PEPTIDE FRACTIONATION BY LIQUID CHROMATOGRAPHY AND  
IDENTIFICATION BY MASS SPECTROMETRY
Several types of chromatography are used to reduce the 
sample complexity or to complement protein and peptide 
separation by electrophoresis. In liquid chromatography 
(LC), the analyte is dissolved in a liquid phase without 
chemically interacting with it, and percolates a stationary 
phase usually packed into one19 or several columns with 
different stationary phases, such as in Multi-dimensional 
Protein Identification Technology (MudPIT)20,21.
Although the analytes are characterized by molecular 
mass (and IP in 2-D) and purified or fractionated by chro-
matography, they need to be identified; this is performed 
by mass spectrometry22. The technique basically consists of 
ionizing a compound and evaluating the ion mass/charge 
(m/z) ratio. The equipment comprises a ionization source, 
one or two mass analyzers and a detector. The first com-
ponent is used to generate peptide or protein ions, usually 
transferring protons (H+) to the molecules without modi-
fying their chemical structure. The ion is accelerated by 
an electric field and separated by m/z in a mass analyzer, 
or it is selected according to a previously determined m/z, 
being fragmented in a tandem process (MS2 or MS/MS). 
Finally, the ions pass through the detector, which is con-
nected to a computer with data analysis software19.
IONIZATION METHODS
Currently, two main ionization methods are available 
and used in proteomics, Matrix-Assisted Laser Desorp-
tion/Ionization (MALDI) and Electrospray Ionization 
(ESI), with the former being employed for solid state 
samples and the latter for liquid state samples (Figure 2). 
In MALDI, peptides are co-crystallized with an organic 
matrix, usually alpha-cyano-4-hydroxycinnamic acid. 
After laser bombardment, the matrix sublimates and its 
ions transfer the charge to analytes, resulting in peptide 
ion formation23. One MALDI variant termed Surface-En-
hanced Laser Desorption/Ionization (SELDI) is usually 
employed to analyze a low-molecular-weight proteome 
and uses several matrices or chips that explore the chro-
matographic and biophysical characteristics of different 
proteins. These chips can exhibit hydrophobic surfaces; 
ion exchange surfaces or surfaces with immobilized me-
tallic ions; or even antibodies, receptors, enzymes, and 
ligands with high affinity for specific proteins24. Thus, af-
ter washing out unbound compounds, a matrix is added 
to the chip surface and spectra are acquired through la-
ser ionization. Another MALDI variant is Imaging Mass 
Spectrometry (IMS), allowing peptide and protein mass 
data to be obtained directly from biological tissue sec-
tions. This method offers important advantages over im-
munohystochemical analysis, including speed and inde-
pendence from antibody use25.
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Figure 2 – Ionization methods. (A) ESI method: an 
aqueous solution containing the analyte is forced through 
a capillary needle and ejected as a spray with highly 
charged droplets, which generate analyte ionized forms 
after solvent evaporation. (B) MALDI method: peptides are 
co-crystallized in an organic matrix and ionized after laser 
bombardment.
In contrast with MALDI, in ESI an aqueous solution 
with the analyte is forced to pass through a capillary nee-
dle undergoing high voltage. The solution is ejected as a 
spray with highly charged droplets that generate analyte 
ionized forms after the solvent is evaporated by a heated 
inert gas flow26.
TYPES OF ANALYZERS
Regardless of the ionization method, the ion molecular 
mass is assessed in an analyzer after passing through a 
vacuum chamber. The most common analyzers are Time 
Of Flight (TOF), quadrupole (Q), and ion trap (IT)19.
In TOF analyzers, the ions resulting from the first step 
are accelerated by a potential between two electrodes and 
pass through a vacuum tube at a speed that is inversely 
related to their mass. When the ions reach the detector, 
the time elapsed from the ionization up to the detection is 
used to derive the m/z value. In fact, the detector converts 
the signal of the ion passage into an analog signal, which is 
read and interpreted by a workstation. The final result is a 
plot of m/z versus intensity (ion count), usually referred to 
as MS spectrum27. The generated signals are compared with 
information available in databases, such as MASCOT28 
and SEQUEST29, to identify the protein of interest.
One of the limitations of the MALDI-TOF system is 
that the detection of low-molecular-weight proteins is dif-
ficult, as they generate few peptides. The system is also 
not able to detect more than one component in a mixture. 
TOF analyzers may be combined with Q analyzers, which 
have a set of four-rod electrodes and work as mass filters 
so that their performance can be improved. Between these 
electrodes, an electric field ensures that only ions with a 
certain m/z ratio travel to the detector, while the others 
are deflected30.
The IT analyzers filter and entrap ions of interest in 
a tridimensional electric field and these are gradually re-
leased in an m/z ascending order31. Fourier Transform 
Ion Cyclotron Resonances (FT-ICRs) are ion traps with 
an additional magnetic field forcing ions to exhibit a cir-
cular movement with high frequency cycles. The analyzer 
determines the m/z ratio from the cyclotronic movement 
frequency by using the Fourier transform19. Orbitrap is an-
other type of IT analyzer wherein ions oscillate along and 
around a single spiral electrode. This oscillation frequency 
is directly related to the square root of the m/z ratio and 
can be determined with high accuracy32,33. This technology 
has migrated towards hybrid systems with two indepen-
dent mass spectrometers that combine, for example, an ion 
trap and an orbitrap, or an ion trap and a FT-ICR.
PROTEIN IDENTIFICATION
After determining the m/z ratio of the intact peptide, its 
sequencing can be performed through a second MS event, 
as described above: more abundant peptides are specifi-
cally selected and undergo fragmentation by collision with 
an inert gas (collision-induced dissociation – CID) or by 
electron transference (ETD); the latter is advantageous 
for preserving protein post-translational modifications in 
top-down analysis. The parental peptide fragmentation 
occurs predominantly along its skeleton, usually between 
the carbonyl oxygen and the amide nitrogen, thus generat-
ing two ion groups termed y and b. The resulting MS/MS 
spectrum is, in fact, a list of m/z ratios for distinct frag-
ments whose mass differences correspond to single amino 
acids. Evaluating these size-ascending fragments from the 
N-terminus (b ion series) or the C-terminus (y ion series) 
allows for deducing the peptide sequence. With the results 
for several peptides, the protein can be identified33.
QUANTITATIVE METHODS
In recent years, several methods of absolute and relative 
protein quantification in samples assessed by MS have 
been developed. Originally, the only available platform 
was 2-D gel, a technology that allows for the assessment of 
hundreds or thousands of protein spots, despite its limita-
tions9. More recently, some methods use protein or peptide 
labeling by isotopes or other reactants identifiable by MS, 
such as linkers with heavy isotopes in Isotope-coded Af-
finity Tag (ICAT)34, Isobaric Tags in Isobaric Tags for Rela-
tive and Absolute Quantification (iTRAQ)35 and in vivo 
labelling of proteins with amino acids containing nonra-
dioactive isotopes in Stable Isotope Labeling with Amino 
acids in Cell Culture (SILAC)36. In short, two samples to 
be compared are covalently modified by isotopes (e.g., 1H 
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versus 2H, 12C versus 13C) and differences in protein quan-
tities are determined by the intensity ratio of differentially 
labeled peptides.
Labeling-free quantification methods have also been 
developed thanks to technological advances in liquid 
chromatography and mass spectrometry systems, as well 
as in bioinformatics tools for data interpretation37. As an 
example, the intensity of peaks of mass spectra generated 
by peptide ions is correlated with abundant protein. The 
same is observed regarding the count of MS/MS spectra, 
as Old et al.38 noted.
APPLICATIONS IN THE STUDY OF HUMAN DISEASES
Although the proteome fraction possibly identifiable by us-
ing the approaches described above has been growing, the 
analysis is still incomplete even in simpler cells, especially 
for low-abundance (such as receptors, signal transducers, 
and regulators), basic, and hydrophobic proteins, as well 
as membrane proteins or those with molecular mass above 
150 kDa or below 10 kDa39. This picture is supposed to 
change because methodologies and technologies in this 
field have had great advances over the last years and have 
reached high levels of resolution and application potential. 
As expressed by Walsh et al.40, proteomics has moved from 
the question “what?” towards questions involving “when, 
where, how, and how much”.
However, what are the benefits of proteomic studies for 
human disease management? The literature on this sub-
ject is extensive, and many relevant data have already been 
obtained, including the characterization, albeit partial, of 
proteins in different tissues and conditions, and of subpro-
teomes, such as phosphoproteomes41 and glycoproteomes42.
However, specific and sensitive biomarkers are not 
easily identified through proteomic approaches. This is re-
vealed, for example, by data obtained from head and neck, 
breast, colon, and ovarian cancers43-45; although they are 
different conditions, they show similar changes. Only one 
screening test (OVA1) developed with the SELDI-TOF 
methodology for ovarian cancer has been approved46,47.
Tissues affected by most human diseases are not easily 
accessible for analysis and they will be unlikely to be used in 
routine analysis. One of the main limitations is cell hetero-
geneity, possibly leading to inaccurate results if a thorough 
histopathological study is not performed. Laser microdis-
section overcomes this problem, but it generates a reduced 
number of cells and introduces extra sample handling. In 
contrast, body fluids have characteristics that surpass these 
limitations and are appropriate for developing low- or less-
invasive diagnostic and prognostic tools. Moreover, they 
are especially appropriate when longitudinal monitoring is 
required32. Prostate specific antigen (PSA) in prostate can-
cer, and tyrosine kinase receptor CD340 in breast cancer 
are good examples that proteins released into the blood 
by diseased tissues can be illness indicators when the con-
centration is altered48. However, there are many technical 
challenges in the use of these biological materials, with the 
most important being the complexity, the dynamic charac-
teristic of the protein composition, and the need to analyze 
a great number of patients to determine intra- and inter-
individual variability for a potential marker. In addition, 
one marker alone would hardly have enough sensitivity 
and specificity for prediction or diagnosis for developing 
clinical tests; protein panels associated with specific condi-
tions will likely be required.
Several organ-specific body fluids have already been 
characterized aiming at clinical use, such as urine for 
Anderson-Fabry disease49; cerebrospinal fluid for multiple 
sclerosis50 and amyotrophic lateral sclerosis51, Alzheimer 
disease52, Creutzfeldt-Jakob disease53, and Parkinson dis-
ease54; bronchioalveolar lavage for chronic obstructive pul-
monary disease55; synovial fluid for osteoarthritis56; tears 
for keratoconus57; and nipple aspirate for breast cancer58.
BODY FLUIDS: SALIVA
Saliva is a biological material well studied by proteomic 
approaches. Comprising a mixture of components secret-
ed by salivary glands and derived from the blood, it is like-
ly the most accessible fluid in our body59. It plays an im-
portant role in supporting oral health by participating in 
processes such as dental enamel remineralization, defense 
against microorganisms, lubrication, digestion, and pH 
and taste modulation59-62. These attributes result from the 
component characteristics, including proteins, hormones, 
small molecules (such as urea), and electrolytes (such as 
calcium, bicarbonate, phosphate, and fluoride)59. Salivary 
proteins have been studied by traditional and proteomic 
biochemical techniques, and hundreds have already been 
identified both in total saliva and in individual gland se-
cretion, although those expressed in low levels certainly 
have not yet been detected57,63-89.
The great interest in saliva as a fluid for diagnosis has 
led to a standardization of collection and storage process-
es90 mainly because several factors affect saliva flow and 
composition. Among these factors, physiological status, 
drugs, foods, odors, circadian rhythm, gender, age, blood 
composition, and degree of salivary gland activity91,92 are 
noticed. Thus, flow parameters and salivary composition 
have been explored in monitoring hormone93 and drug94 
levels, exposition to environmental pollutants95 and in-
fectious agents96, and disease monitoring, including peri-
odontitis97, diabetes mellitus98, cystic fibrosis99, Sjögren 
syndrome100, salivary gland diseases101, and breast102,103, 
ovarian104, and oral105,106 cancer. Regarding oral cancer, the 
anatomic site offers saliva an important advantage over 
other fluids, in addition to the noninvasive characteristic 
and the compatibility with proteomic approaches. Being 
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Figure 3 – Gels resulting from 2-D serum protein 
electrophoresis from patients with neuroﬁbromatosis. (A) 
Without and (B) with depletion of more abundant proteins.
in contact with the affected tissue, thus receiving proteins 
secreted or derived from dead cells, its potential use ranges 
from early detection107 to aggressiveness prediction and 
prognostics108.
Although many studies have identified salivary bio-
markers in local and systemic diseases, their validation 
in large sample groups is not available, and data from 
different authors on the same disease show conflicting 
results109. Nevertheless, a number of interesting associa-
tions have been reported. For example, elevated transfer-
rin levels were observed in patients with oral carcinoma, 
correlated with tumor size and stage. Assays for ELISA 
were highly specific and sensitive for early detection of 
this carcinoma, which makes transferrin a promising 
marker110. This protein is essential for cells with a high 
proliferation level, and is involved in DNA synthesis and 
transduction paths of mitogenic signals111.
Regarding the potential of therapy response predic-
tion, recently Vidotto et al.112 observed that the levels of 
some salivary proteins in patients with head and neck 
carcinoma revert to a pattern similar to that observed in 
healthy individuals after treatment. Among these proteins, 
two of them (PLUNC and ZN-alpha-2-GP) are related to 
inflammation, which is frequently found in these tumors.
BODY FLUIDS: SERUM/PLASMA
Although saliva and other body fluids allow for obtaining 
relevant data for proteomic analysis, mainly in diseases 
affecting specific tissues and organs, no question remains 
that serum and plasma are much more comprehensive. 
These blood fractions are among the most important 
sources of biological markers and can provide rich infor-
mation about physiological and pathological processes113. 
Their analysis for diagnostic purpose is well known, and 
both fractions are similar in composition. However, plas-
ma appears to be more stable and more appropriate than 
serum to assess low-molecular-weight proteins. On the 
other hand, serum is the material of choice for several 
tests because plasma anticoagulants interfere with some 
methods employed44.
Only 22 proteins, such as albumin, transferrin, hap-
toglobin, immunoglobulins, and lipoproteins make over 
95% of serum/plasma proteome. Many cell proteins, in 
contrast, enter circulation in very reduced levels114. As an 
example, albumin is found in blood in a millimolar (10-3 
mol) concentration, while other proteins, such as cyto-
kines, have an activity in concentrations between 10-12 
mol and 10-9 mol115. This smaller group certainly includes 
disease biomarkers116 whose detection unfortunately may 
be interfered with by very abundant proteins. In a review 
by Kawashima et al.117, various depletion methods are 
used; however, they often result in the removal of low-
molecular-weight proteins (Figure 3).
Schiess et al.48, by comparing known markers with pro-
teins identified by proteomic approaches, observed plas-
matic concentrations with very different orders of magni-
tude. While levels of markers such as PSA and CD340 are 
in the range of pg to ng/mL, the levels of classic plasma 
proteins are in the order of μg to mg/mL. These data show 
the need for advances in technology so that detection limits 
reach lower concentration levels114. Recently, measurements 
by Selected Reaction Monitoring (SRM) in mass spectrom-
etry have been used to overcome these difficulties, as they 
focus on a priori selected protein sets which have generated 
very consistent data118,119, especially when abundant com-
ponent depletion and fractionation are combined120.
Despite these limitations, many data have already been 
obtained from the serum/plasma of patients with diabe-
tes121,122; autoimmune diseases123; heart124 and infectious125 
diseases; Parkinson126 and Alzheimer52 diseases; endome-
triosis127; bladder128, head and neck129-132, colon133,134, esoph-
agus135, stomach136, liver137,138, breast139,140, pancreas141,142, 
prostate143,144, lung145,146, and kidney147-149 tumors; and also 
pregnant women with fetuses with Down syndrome150.
Although the number of publications is high, only one 
screening test developed from proteomic approaches has 
been approved (OVA1). The test analyzes a protein panel 
(CA125, transthyretin or prealbumin, apolipoprotein A1, 
beta-2-microglobulin, and transferrin) and, when com-
bined with clinical and imaging evaluation, presents a 
sensitivity higher than 90% for pre-surgical assessment of 
ovarian cancer risk46,47.
FINAL CONSIDERATIONS
Many factors affect the results of proteomic analysis, es-
pecially regarding body fluids. Patient and environmental 
characteristics are among these factors44,151. In the pre-ana-
lytical stage, material processing introduces other variables, 
such as collection method, type of storage, and initial sam-
ple treatments. Likewise, proteolytic breakdown products 
generated in the analytical stage influence the results if ef-
fective protease inhibitors are not used. Breakdown by ca-
tabolism is equally important152, although low-molecular-
weight fragments are not always nonspecific, such as those 
derived from transthyretin153 and osteopontin154.
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The clinical aspect of proteomic studies has also faced 
a few challenges. One of them is prospective analysis of 
representative and well-characterized populations to ac-
quire statistical power and surpass the limitations result-
ing from individual variability and biological material 
processing.
Despite these challenges, there is no doubt that the 
results of proteomic approaches are potentially useful in 
several clinical research areas, such as diagnosis, therapy 
response monitoring, endpoint prediction, disease sub-
type classification, risk determination, characterization 
of metabolic pathways, biomarker quantification, and 
therapeutic target generation40.
In recent years, many important biological questions 
have been answered by proteomics and hundreds of can-
didate biomarkers have been introduced. However, few 
markers have surpassed the identification stage. Their 
successful application to clinical practice will depend on 
sensitive platforms; development of protein panels; and 
collaborative studies including physicians, epidemiolo-
gists, molecular biologists, and bioinformaticians with a 
relevant clinical issue and well-defined recruitment and 
characterization parameters for patients and samples.
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